Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novasep is planning to invest €30m to construct chromatography plant for the production of a large volume commercial API (active pharmaceutical ingredient) in Europe.
Subscribe to our email newsletter
The proposed plant will be built on Novasep’s existing Mourenx site in France and is expected to be operational and validated within 18 months.
The new plant will include Varicol systems with 1,200 mm diameter columns operated at up to 70 bars, the largest ever built in the pharmaceutical industry, as claimed by the company.
The plant will produce purified API from a complex mixture while the Varicol systems will integrate sophisticated solvent recovery systems to recycle 99.9% of solvents.
Novasep president and CEO Patrick Glaser said demand for Novasep’s advanced, purification-based manufacturing capabilities in the life science industries is increasing as drugs in development and reaching the market become more complex and specific.
”This necessitates our third, and largest global plant expansion in 2012,” Glaser added.
"This successful project, the world’s largest chromatography plant in the pharmaceutical industry, demonstrates the validity of the Novasep strategy which is based on the combination of synthesis, biosynthesis and purification."